<qa>  What is the name of the monoclonal antibody licensed for the treatment of metastatic cancerSmall, uncontrolled studies with intravitreal injection into the vitreous space of the eye bevacizumab Avastin suggest that this agent enhances clearance of diabetic vitreous haemorrhage1,2,3. Bevacizumab is a monoclonal antibody licensed for the treatment of metastatic cancer. It works by inhibiting vascular endothelial growth factor VEGF, a chemical mediator that promotes new blood vessel growth within tumours. It has been used off-label without a licenceto treat neovascular age-related macular degeneration nAMD - a common eye disease with loss of vision, and other conditions characterised by intraocular new blood vessel growth neovascularisation. 